KEYPAD
21 Dec 2020
Trial Summary
This study is designed to test the safety and potential benefit of adding an existing drug used for bone protection (denosumab) to a new immune stimulating drug (pembrolizumab).
Acronym:
ANZUP1601
ACTRN/NCT /ethics:
ACTRN12618000132246
Scientific title:
Denosumab and Pembrolizumab in clear cell renal carcinoma
Sponsor / Cooperative group:
Merck Sharp & Dohme Corp.
Trial & Patient Characteristics
| Cancer Type | Kidney |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | All stages |
| Anticipated Start Date | 2017-12-12 |
| Anticipated End Date | 2022-12-31 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Hannah Adelson |
| Hannah.adelson@sa.gov.au | |
| Phone | 08 8206 4835 |
| Principal Investigator | Dr Sina Vatandoust |
| Recruitment Status | Recruiting |